BNIP3 and lung carcinoma: Consistent with the results of previous studies18, 39, although BafA1 treatment downregulated lung cancer cell motility (Fig. 2b,c), ATG12 siRNA and BNIP3 shRNA also impaired cell migration in CL1-5 cells (Fig. S2).